Esperion Therapeutics (NASDAQ:ESPR) was upgraded by equities research analysts at Citigroup from a “neutral” rating to a “buy” rating in a research note issued to investors on Friday, The Fly reports. The firm currently has a $75.00 target price on the biopharmaceutical company’s stock, up from their previous target price of $57.00. Citigroup’s price objective suggests a potential upside of 50.84% from the company’s previous close.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.